« Back
Home /
Bucillamine

Bucillamine

Item no.	TMO-T21334-1g
Manufacturer	TargetMol
CASRN	65002-17-7
Amount	1 g
Quantity options	1000 mg 100 mg 10 mg 1 g 1 mL 200 mg 25 mg 500 mg 50 mg 5 mg
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Citations	Matsuno H, Okada M, Sakai Y, Abe C, Katayama K, Sagawa A, Yamasaki K, Kondo M, Funahashi K, Matsubara T. The Usefulness of a New Triple Combination Treatment Utilizing methotrexate, salazosulfapyridine, and bucillamine in Rheumatoid Arthritis. Mod Rheumatol. 2015 Jun 8:1-20. [Epub ahead of print] PubMed PMID: 26052803.
Smiles	[C@@H](NC(C(C)(C)S)=O)(C(O)=O)CS
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	DE-019, Tiobutarit, Thiobutarit, DE019, DE 019, SA96
Shipping condition	Cool pack
Available
Manufacturer - Targets	VEGFR\|\|\|Antioxidant
Shipping Temperature	cool pack
Storage Conditions	-20°
Molecular Weight	223, 31
Description	Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis.
Bioactivity	Bucillamine is an antirheumatic agent. Its activity is mediated by the two thiol groups in the molecule. Research done in USA showed positive transplant preservation properties.
Pathways	Tyrosine Kinase/Adaptors\|\|\|oxidation-reduction\|\|\|Angiogenesis

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T21334-1g-datasheet.pdf

TMO-T21334-1g-safety-datasheet.pdf